The Laura Bassi Scholarship was established by Editing Press in 2018 with the aim of providing editorial assistance to postgraduates and junior academics whose research focuses on neglected topics of study, broadly construed, within their disciplines.

The AACR-The Mark Foundation for Cancer Research "Science of the Patient" (SOP) Grants Program represents a joint effort to stimulate novel research aimed at understanding the influence of the biology of the host (i.e., patient) on the genesis, development, treatment, and survivorship of cancer. Successful projects should emphasize the interplay of host physiological systems with the tumor and/or tumor microenvironment. Harnessing the powerful approach of examining cancer not as an isolated phenomenon but as a systemic disease that affects and is affected by both the normal and pathological functions of the patient's body, these grants are expected to yield important advancements in our understanding of cancer development, progression, and treatment. Individuals with innovative ideas that have the potential to affect future clinical practice are particularly encouraged to apply.  Each grant will provide $750,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient and any collaborators, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies; equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; other research expenses; and indirect costs.

The BTSI is awarded to scientists at the end of their fellowship or in the beginning of their faculty appointment, who are predominantly focused on lab-based, basic/translational research. The BTSI is intended to encourage scientific inquiry in the field of basic/translational science as it relates to NETs. NANETS welcomes applications from candidates who meet the following criteria: - Candidates must have a MD, PhD, MD/PhD, DO degree or equivalent. - At the time of funding, candidates must be in the first 6 years of a faculty appointment at an accredited medical school or other institution in North America. Faculty appointments include instructors and above. - Candidates must be a NANETS member in good standing. - Previous recipients of NBTSI, NCIS or NTIG awards are not eligible to apply. Criteria for selection will include both the research proposal itself and the potential of the individual to make future scientific and/or clinical contributions to the neuroendocrine tumor field. Strong emphasis will be placed on the career development plan and the applicant's personal statements, as well as the research proposal. The research proposals section should focus on research projects with the potential to directly impact and improve the treatment of patients with neuroendocrine tumors.

In November 2018, the Moore Foundation announced its Diagnostic Excellence Initiative with a focus on diagnostic performance improvement. The initiative aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes and save lives. The initiative's first area of focus is to develop and validate new measures for diagnostic performance. Examples of our first cohort of grants for diagnostic clinical quality measures are now available for review. Starting with measure development is important - currently, U.S. health care systems are unable to systemically measure diagnostic performance in real time, which limits the ability to quantify performance and guide improvements. 

Each year, CLRA's Medical Advisory Committee, consisting of prominent internationally known and respected hematologists, reviews submitted research proposals from doctors nationwide. Using your contributions, we fund research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this dread disease. The objectives of this committee are to direct the funds of the Association into the most promising projects, and where funding would not duplicate other funding sources. With your help, we are getting closer every day! Because of the support of friends like you, the scientific community is making incredible strides in developing chemotherapy regimens that are extending the lives of leukemia patients. Not everyone under treatment goes into remission but our research grants are funding the examinations into why this is so, and how we can continue to combat leukemia.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee. Applications will be evaluated based on the following:  - The applicant's capacity to conduct bold, exceptionally creative research. - The novelty and creativity of the proposed research. Incremental research will not be funded. - The potential of the proposed research to lead to advances that will significantly impact the prevention, diagnosis, treatment or basic understanding of cancer. - The applicant's lack of resources to pursue the proposed research.

The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.

Conducting exceptional clinical research requires close collaboration between academic and industry professionals. Our year-long Clinical Research Fellowships in Oncology, Neurology, Immunology, Ophthalmology, Pulmonary Medicine and other specialty areas give fellows the crucial experience they need to transform knowledge into practice, working directly with top institutions and physicians to strengthen our commitment to developing innovative new medicines.

The Mark Foundation Emerging Leader Awards support innovative research from the next generation of leaders in cancer research. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.

The purpose of the FOA is to support the development of collaborative, multi-disciplinary basic research centers to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. It is anticipated that each center will use systems-level approaches that encompass chronological progression and biological scales to derive a more comprehensive and cohesive picture of metastasis. Centers may derive new physiologically relevant models that capture the entire metastatic process or develop new experimental and analytical technologies or probes for tracking and monitoring the in vivo dynamics of metastatic cell states.

The FY20 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research. A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations Also listed under: -Translational Research Partnership Award -Early-Career Investigator Award

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

To that end, the foundation is inviting applications for innovative research with the potential to increase the basic understanding of these uncommon tumors and lead to the development of more effective therapies. Grants ranging between $100,000 to $1.2 million will be awarded in support of projects over one to four years in the areas of basic, translational, or clinical neuroendocrine cancer research. Four different grants will be awarded: Accelerator Award - Grants of up to $1.2 million over four years will be awarded to projects that bring together investigators from diverse scientific disciplines. Investigator Awards - Grants of up to $300,000 over two years will be awarded to investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways. Pilot Awards - Grants of up to $100,000 over one year will be awarded for pilot studies. Mentored Awards - Grants of up to $120,000 over two years will be awarded to encourage early-career investigators to pursue neuroendocrine tumor research and make a commitment to the field.

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

The AACR-Bayer Stimulating Therapeutic Advances through Research Training (START) Grants represent an exciting initiative to encourage and support collaboration between academia and industry. This novel model provides support for three years to postdoctoral and clinical research fellows working on a mentored cancer research project and includes one year spent on site at a Bayer facility. The combined academic and industry training provided through this program will be invaluable to young investigators, allowing them to attain a comprehensive research experience. Projects must have direct applicability and relevance to clinical translation and development in solid tumors and hematologic malignancies.

To that end, the foundation is accepting proposals for innovative leukemia research. Grants of up to $50,000 over a year will be awarded to new and established investigators for lab, translational, or clinical research related to acute leukemia. Renewals of initial research support may be considered for one or more additional years based on productivity.

Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The current Program Announcement discusses the Breakthrough Award Level 3. Funding Levels 1, 2, and 4 are available under other Program Announcements (W81XWH-20-BCRP- BTA12-2 for Levels 1 and 2 and W81XWH-20-BCRP-BTA4-2 for Level 4). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award Program Announcements before submitting the pre- application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.